Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
Our own Dr. Brian Koffman spoke with Dr. Andrea Sitlinger, Assistant Professor of Medicine and hematologist at Duke Cancer Center in Durham, NC. They talked about the results of a pilot study on high-intensity interval training for older adults with CLL or SLL.
CLL and SLL patients with deletion 17p do not respond well to chemoimmunotherapy. But new targeted therapies may help. Zanubrutinib is a next-generation BTK inhibitor being tested in combination with venetoclax for treating patients with deletion 17p. Results from a Phase III trial of this combination were presented at the 2021 ASH meeting.
Over the course of a year of monthly meetings, the CLL Bloodline will teach the BASICS needed to understand CLL, bring news, help with the acronyms and new vocabulary, and offer
Dr. Jeff Sharman and colleagues presented this research at the American Society for Hematology annual meeting held December 2021 (ASH 2021).
This should be good news for CLL / SLL patients. If things go as planned, we could have FDA approval of a third irreversibly binding BTK inhibitor, zanubrutinib, before the end of the year.
Dr. Charis Teh and colleagues presented this research at the American Society for Hematology annual meeting, which was held in December 2021 (ASH 2021). Background: Venetoclax is a highly effective treatment
Clinical Trial Results Clinical Trial Results No drugs receive FDA approval for use in CLL / SLL or come to market without being first evaluated for safety, efficacy, dosage, and many other factors
In this study presented at the American Society of Hematology Annual Meeting and Exhibition (ASH 2021), researchers are doing pre-clinical studies on CLL cells to develop alternative approaches to prevent or overcome resistance.
Question: I understand because of “when” I received my Pneumonia shots, I now need to get another shot due to updated medical expert recommendations. I want to proceed. Are there just
One click to our most popular content.
